Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish? Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects. Barchart · May 14, 2024
Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield? Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now? Barchart · Feb 21, 2024
Gilead Sciences (GILD) Earnings Forecast and Gameplan Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on. StockNews.com · Nov 6, 2023
Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks? As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell. StockNews.com · Sep 18, 2023
3 Biotech Stocks With Some Major Value in Them The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read… StockNews.com · Jun 27, 2023
3 Biotech Stocks Every Investor Wants Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on. StockNews.com · Jun 21, 2023
Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet... Barchart · May 16, 2023
Pharmaceutical executives challenge Texas court’s abortion pill ruling Gilead Sciences and Pfizer join amicus brief The Independent UK · Apr 12, 2023
2 Biotech Stocks to Buy Hand Over Fist in March The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading. StockNews.com · Mar 23, 2023
3 Dividend Paying Stocks to Buy in March With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading. StockNews.com · Mar 21, 2023
It’s Time to Buy Up These 3 Growth Stocks In 2023 While higher rates have hurt growth stocks last year, 2023 could be the year of growth stocks gaining momentum. Amid rising optimism, investors could consider buying fundamentally strong growth stocks Gilead Sciences (GILD), Jazz (JAZZ), and Masonite International (DOOR) this year. Keep reading. StockNews.com · Feb 23, 2023
2 Biotech Stocks to Buy and 1 to Avoid Like the Plague The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental… StockNews.com · Jan 19, 2023
3 Safe High-Dividend Stocks to Buy Right Now While inflation pressures seem to be cooling, the Fed is expected to continue with its rate hikes, raising the chances of a recession this year. Hence, high-dividend stocks AbbVie (ABBV), Gilead Sciences (GILD), and Marine Products (MPX) might be solid buys for steady income amid current uncertainties. Keep reading. StockNews.com · Jan 18, 2023
Up More than 19% In 2022, Is Gilead Sciences Still a Buy? Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view. StockNews.com · Dec 20, 2022
The Conversation · Nov 21, 2022 Monkeypox: latest data reveals how the virus has affected women and non-binary people Since May 2022, a global outbreak of human monkeypox infections has been reported in over 78,000 people. So far, infections have overwhelmingly occurred in sexually active men who have sex with men.
StockNews.com · Nov 14, 2022 Is Gilead Sciences Still a Buy Post COVID-19? Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…
Benzinga · Nov 8, 2022 Gilead Sciences Unusual Options Activity Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · Oct 28, 2022 Check Out What Whales Are Doing With GILD Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Reuters · Oct 18, 2022 U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.
Benzinga · Oct 12, 2022 Gilead Sciences Whale Trades Spotted Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
StockNews.com · Oct 6, 2022 3 Biotech Stocks to Buy for Q4 and 1 to Avoid Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….
Benzinga · Oct 4, 2022 What Are Whales Doing With Gilead Sciences A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.